PTC Therapeutics Inc (NASDAQ: PTCT) has reported E.P.S. of $-0.85 for its fourth fiscal quarter (ending December 31) versus $-2.06 for the same period a year ago — a decline of -59%. For the latest four quarters through December 31, E.P.S. were $-4.73 compared to $-8.37 a year ago — a decline of -43%.
Recent Price Action
PTC Therapeutics Inc (NASDAQ: PTCT) stock closed at $50.57 on 2/27/25 after a slight decline of -0.8%. Moreover, above average trading volume at 144% of normal accompanied the decline. The stock is unchanged during the last week and has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
PTC Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.